Susan Rosencrance, Ph.D., serves as the Acting Director of the Office of Generic Drugs (OGD) in the Center for Drug Evaluation and Research (CDER). This office is responsible for the review and approval of abbreviated new drug applications. OGD’s mission is to ensure, through a scientific and regulatory process, that generic drugs are safe and effective for the American public.
From 2015 to 2022, Dr. Rosencrance served as the Director of the Office of Lifecycle Drug Products within CDER’s Office of Pharmaceutical Quality (OPQ). She joined FDA in 1991, where she served in various roles within the Office of Generic Drugs and as the Deputy Director for Generic Drug Chemistry in CDER’s former Office of Pharmaceutical Science, prior to the formation of OPQ.
Before joining FDA, Dr. Rosencrance worked in research and development at Merck and Company. She holds a Ph.D. in chemistry from American University in Washington, D.C., and completed her dissertation research at the NIH Laboratory of Biophysical Chemistry. She received her bachelor’s degree in biochemistry from Hood College and completed studies at the IIEP - University of Louis-Pasteur in the University of Strasbourg, France.